Genmab A/S (NASDAQ:GMAB) Expected to Post Earnings of $0.10 Per Share

Equities research analysts expect that Genmab A/S (NASDAQ:GMABGet Rating) will post earnings of $0.10 per share for the current quarter, according to Zacks. Four analysts have issued estimates for Genmab A/S’s earnings. The highest EPS estimate is $0.26 and the lowest is $0.02. Genmab A/S posted earnings of $0.27 per share during the same quarter last year, which would indicate a negative year over year growth rate of 63%. The firm is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Genmab A/S will report full-year earnings of $0.78 per share for the current fiscal year, with EPS estimates ranging from $0.63 to $0.87. For the next year, analysts expect that the company will report earnings of $1.13 per share, with EPS estimates ranging from $0.91 to $1.57. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Genmab A/S.

Genmab A/S (NASDAQ:GMABGet Rating) last issued its earnings results on Wednesday, February 16th. The company reported $0.17 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.04. The business had revenue of $402.74 million during the quarter, compared to the consensus estimate of $387.16 million. Genmab A/S had a return on equity of 14.23% and a net margin of 35.58%.

Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Genmab A/S from a “hold” rating to a “sell” rating in a report on Thursday, January 20th. JPMorgan Chase & Co. decreased their price objective on Genmab A/S from 3,200.00 to 3,100.00 in a report on Friday, February 25th. Morgan Stanley decreased their price objective on Genmab A/S from $33.00 to $30.00 and set an “underweight” rating for the company in a report on Tuesday, April 12th. SVB Leerink decreased their price objective on Genmab A/S from $42.00 to $39.00 and set a “market perform” rating for the company in a report on Thursday, February 17th. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Genmab A/S in a report on Thursday, March 17th. Four equities research analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Genmab A/S presently has an average rating of “Hold” and an average target price of $480.86.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GMAB. Liberty Wealth Management LLC grew its stake in Genmab A/S by 285.6% in the 3rd quarter. Liberty Wealth Management LLC now owns 671 shares of the company’s stock valued at $28,000 after purchasing an additional 497 shares during the period. Covestor Ltd bought a new position in shares of Genmab A/S during the 4th quarter worth $37,000. Cordasco Financial Network grew its stake in shares of Genmab A/S by 40.8% during the 3rd quarter. Cordasco Financial Network now owns 915 shares of the company’s stock worth $40,000 after acquiring an additional 265 shares during the period. Bessemer Group Inc. grew its stake in shares of Genmab A/S by 50.3% during the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock worth $46,000 after acquiring an additional 387 shares during the period. Finally, Captrust Financial Advisors grew its stake in shares of Genmab A/S by 23.2% during the 3rd quarter. Captrust Financial Advisors now owns 1,414 shares of the company’s stock worth $62,000 after acquiring an additional 266 shares during the period. 6.09% of the stock is owned by institutional investors and hedge funds.

NASDAQ GMAB opened at $36.46 on Wednesday. The company has a market cap of $23.97 billion, a price-to-earnings ratio of 49.95, a P/E/G ratio of 1.67 and a beta of 1.04. Genmab A/S has a 52 week low of $30.08 and a 52 week high of $49.07. The business has a 50 day moving average price of $34.88 and a 200-day moving average price of $37.82.

About Genmab A/S (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

See Also

Get a free copy of the Zacks research report on Genmab A/S (GMAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.